-
March 10, 2022 My Favorite Psychedelic Stocks: Part 1Our resident Psychedelic Investor details five companies he thinks are in strong position to win...
-
February 9, 2022 DMT Vape Pen Patent Illustrates a Big Problem in the Psychedelics IndustryProblematic patents have serious implications for the entire psychedelics industry.
-
December 17, 2021 Psychedelic Business Spotlight – December 17This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints...
-
December 13, 2021 Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic EffectChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could...
-
December 3, 2021 Psychedelic Business Spotlight: December 3This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a...
-
December 1, 2021 Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialChief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients...
-
November 26, 2021 Psychedelic Business Spotlight: November 26This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big...
-
November 12, 2021 Psychedelic Business Spotlight: November 12This week in psychedelic business news: two of the biggest players in the industry unveil...
-
November 9, 2021 Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,”...
-
November 5, 2021 Psychedelic Business Spotlight: November 5This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher...
